These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29881820)

  • 1. Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis.
    Carbone M; Harms MH; Lammers WJ; Marmon T; Pencek R; MacConell L; Shapiro D; Jones DE; Mells GF; Hansen BE
    Hepatol Commun; 2018 Jun; 2(6):683-692. PubMed ID: 29881820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis.
    Harms MH; Hirschfield GM; Floreani A; Mayo MJ; Parés A; Liberman A; Malecha ES; Pencek R; MacConell L; Hansen BE
    JHEP Rep; 2021 Feb; 3(1):100191. PubMed ID: 33319187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls.
    Murillo Perez CF; Fisher H; Hiu S; Kareithi D; Adekunle F; Mayne T; Malecha E; Ness E; van der Meer AJ; Lammers WJ; Trivedi PJ; Battezzati PM; Nevens F; Kowdley KV; Bruns T; Cazzagon N; Floreani A; Mason AL; Parés A; Londoño MC; Invernizzi P; Carbone M; Lleo A; Mayo MJ; Dalekos GN; Gatselis NK; Thorburn D; Verhelst X; Gulamhusein A; Janssen HLA; Smith R; Flack S; Mulcahy V; Trauner M; Bowlus CL; Lindor KD; Corpechot C; Jones D; Mells G; Hirschfield GM; Wason J; Hansen BE;
    Gastroenterology; 2022 Dec; 163(6):1630-1642.e3. PubMed ID: 36150526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world experience with obeticholic acid in patients with primary biliary cholangitis.
    D'Amato D; De Vincentis A; Malinverno F; Viganò M; Alvaro D; Pompili M; Picciotto A; Palitti VP; Russello M; Storato S; Pigozzi MG; Calvaruso V; De Gasperi E; Lleo A; Castellaneta A; Pellicelli A; Cazzagon N; Floreani A; Muratori L; Fagiuoli S; Niro GA; Feletti V; Cozzolongo R; Terreni N; Marzioni M; Pellicano R; Pozzoni P; Baiocchi L; Chessa L; Rosina F; Bertino G; Vinci M; Morgando A; Vanni E; Scifo G; Sacco R; D'Antò M; Bellia V; Boldizzoni R; Casella S; Omazzi B; Poggi G; Cristoferi L; Gerussi A; Ronca V; Venere R; Ponziani F; Cannavò M; Mussetto A; Fontana R; Losito F; Frazzetto E; Distefano M; Colapietro F; Labanca S; Marconi G; Grassi G; Galati G; O'Donnell SE; Mancuso C; Mulinacci G; Palermo A; Claar E; Izzi A; Picardi A; Invernizzi P; Carbone M; Vespasiani-Gentilucci U;
    JHEP Rep; 2021 Apr; 3(2):100248. PubMed ID: 33681748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid.
    Gomez E; Garcia Buey L; Molina E; Casado M; Conde I; Berenguer M; Jorquera F; Simón MA; Olveira A; Hernández-Guerra M; Mesquita M; Presa J; Costa-Moreira P; Macedo G; Arenas JI; Manuel Sousa J; Ampuero J; Morillas RM; Santos A; De Carvalho A; Uriz J; Carrión JA; Luisa Gutiérrez M; Pérez-Fernández E; Fernández-Rodríguez CM;
    Aliment Pharmacol Ther; 2021 Feb; 53(4):519-530. PubMed ID: 33314220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the United Kingdom-primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population.
    Alomari M; Covut F; Al Momani L; Chadalavada P; Hitawala A; Young MF; Romero-Marrero C
    JGH Open; 2020 Apr; 4(2):132-139. PubMed ID: 32280755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.
    Samur S; Klebanoff M; Banken R; Pratt DS; Chapman R; Ollendorf DA; Loos AM; Corey K; Hur C; Chhatwal J
    Hepatology; 2017 Mar; 65(3):920-928. PubMed ID: 27906472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis.
    Honda A; Tanaka A; Kaneko T; Komori A; Abe M; Inao M; Namisaki T; Hashimoto N; Kawata K; Takahashi A; Ninomiya M; Kang JH; Arakawa M; Yamagiwa S; Joshita S; Umemura T; Sato K; Kaneko A; Kikuchi K; Itakura J; Nomura T; Kakisaka K; Fujii H; Kawada N; Takikawa Y; Masaki T; Ohira H; Mochida S; Yoshiji H; Iimuro S; Matsuzaki Y; Takikawa H;
    Hepatology; 2019 Dec; 70(6):2035-2046. PubMed ID: 30737815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External validation of the United Kingdom-primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid.
    Cheung AC; Gulamhusein AF; Juran BD; Schlicht EM; McCauley BM; de Andrade M; Atkinson EJ; Lazaridis KN
    Hepatol Commun; 2018 Jun; 2(6):676-682. PubMed ID: 29881819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis.
    Goet JC; Murillo Perez CF; Harms MH; Floreani A; Cazzagon N; Bruns T; Prechter F; Dalekos GN; Verhelst X; Gatselis NK; Lindor KD; Lammers WJ; Gulamhusein A; Reig A; Carbone M; Nevens F; Hirschfield GM; van der Meer AJ; van Buuren HR; Hansen BE; Parés A;
    Am J Gastroenterol; 2021 Jul; 116(7):1514-1522. PubMed ID: 33941746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis.
    Roberts SB; Ismail M; Kanagalingam G; Mason AL; Swain MG; Vincent C; Yoshida EM; Tsien C; Flemming JA; Janssen HLA; Hirschfield GM; Hansen BE; Gulamhusein AF;
    Hepatol Commun; 2020 Sep; 4(9):1332-1345. PubMed ID: 32923836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.
    Yang F; Yang Y; Wang Q; Wang Z; Miao Q; Xiao X; Wei Y; Bian Z; Sheng L; Chen X; Qiu D; Fang J; Tang R; Gershwin ME; Ma X
    Aliment Pharmacol Ther; 2017 Mar; 45(5):733-743. PubMed ID: 28083929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.
    Bahar R; Wong KA; Liu CH; Bowlus CL
    Gastroenterol Hepatol (N Y); 2018 Mar; 14(3):154-163. PubMed ID: 29928160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
    Kjærgaard K; Frisch K; Sørensen M; Munk OL; Hofmann AF; Horsager J; Schacht AC; Erickson M; Shapiro D; Keiding S
    J Hepatol; 2021 Jan; 74(1):58-65. PubMed ID: 32717289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
    Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
    Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
    Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
    Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis.
    John BV; Schwartz K; Levy C; Dahman B; Deng Y; Martin P; Taddei TH; Kaplan DE
    Hepatol Commun; 2021 Aug; 5(8):1426-1436. PubMed ID: 34430786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW; Lynch KD
    Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.